By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

Novo Nordisk (NVO) is recruiting a new head for its investor relations department: Michael Novod, a top healthcare equity ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Shares of Novo Nordisk fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top ...

The changing of the guard at Novo Nordisk took another turn this week as the company revealed that seven members of its board ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Novo Nordisk will replace chair Helge Lund and six independent directors next month in a major boardroom shakeup following a ...

Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be ...

Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts ...

Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...